Company intelligence / Profile preview
Foreseen Biotechnology
Shanghai, Shanghai Province, Chinaforeseen.bio ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Foreseen Biotechnology has developed a proprietary AI-powered proteomics platform to identify novel therapeutic targets. Its lead asset, FS001—an antibody-drug conjugate targeting a novel tumor-associated antigen—has demonstrated robust preclinical efficacy in multiple solid tumor models, including multidrug-resistant cancers. The company recently outlicensed global rights to FS001 to Ipsen for up to $1.03 billion; Ipsen will advance it into Phase I clinical trials[2][4][5].
- Therapeutic areas
- Oncology
- Modalities
- Antibody-drug conjugateBiologic (platform focus)
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Partnerships
Ipsen SA – exclusive global licensing agreement for ADC candidate FS001 ($1.03B deal)[2][4]
Beyond the preview
Go deeper on Foreseen Biotechnology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Foreseen Biotechnology.